Pradaxa® MDL Update (MDL 2385): $650 Million Settlement Reached in Federal Multidistrict Litigation

Roger C. Denton, Plaintiffs' Co-Lead Counsel and a lead negotiator in the Pradaxa® MDL, reports that a $650 Million settlement has been reached today with Boehringer Ingelheim Pharmaceuticals, Inc. (and affiliates) to settle approximately 4,000 Pradaxa® claims.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friendRepost This

Roger C. Denton, Plaintiffs' Co-Lead Counsel and a lead negotiator in the Pradaxa® MDL

The settlement program announced today is an outstanding result and is in the best interests of our clients who have suffered serious injuries after using Pradaxa®

St. Louis, MO (PRWEB) May 28, 2014

The Plaintiffs’ Steering Committee, appointed by The Honorable Chief Judge David R. Herndon to negotiate the settlement on behalf of all plaintiffs in the Pradaxa® MDL, and Boehringer Ingelheim Pharmaceuticals, Inc. (and affiliates) have negotiated a settlement program in the amount of $650 Million to resolve approximately 4,000 Pradaxa® claims.

Roger C. Denton of Schlichter, Bogard & Denton, LLP serves as Co-Lead Counsel on the Plaintiffs’ Steering Committee in the national Pradaxa® Multidistrict Litigation (MDL 2385) and has been most recently appointed by Chief Judge Herndon to serve as a member of the Pradaxa® Claimants’ Negotiating Committee (PCNC) going forward. “We are pleased to announce that a settlement has been reached to settle approximately 4,000 Pradaxa® cases,” says Roger Denton. He adds, “The settlement was reached after two years of litigation, which entailed fiercely briefing and arguing countless discovery motions, reviewing millions of pages of documents produced by defendants, and the completion of nearly 50 depositions – both in the United States and in Europe.” Denton further states, “The settlement program announced today is an outstanding result and is in the best interests of our clients who have suffered serious injuries after using Pradaxa®.”

Pradaxa®, which is manufactured by Boehringer Ingelheim Pharmaceuticals, Inc. (and affiliates), is a direct thrombin inhibitor and oral anticoagulant. Pradaxa was approved in the United States by the Food and Drug Administration (FDA) as a blood thinning medication used to lower the chance of stroke in patients with non-valvular atrial fibrillation. In 2011, the FDA initiated a formal investigation into serious bleeding events associated with the use of Pradaxa®. Unlike other blood thinning medications, such as warfarin, there is no known reversal agent or antidote for Pradaxa®. Thousands of individuals filed lawsuits against the manufacturers of Pradaxa® alleging injuries suffered after using Pradaxa®, including serious bleeding events. As a result, in August 2012 the Judicial Panel on Multidistrict Litigation (JPML) consolidated the federal court claims into a Multidistrict Litigation (In re: Pradaxa® (Dabigatran Etexilate) Products Liability Litigation, MDL 2385) before The Honorable Chief Judge David R. Herndon in the United States District Court for the Southern District of Illinois.

About Schlichter, Bogard & Denton, LLP
Schlichter, Bogard & Denton, LLP is a unique law firm that has held numerous leadership positions in other national litigations involving dangerous pharmaceutical medications and unsafe medical devices, including but not limited to: In re: Yasmin® and Yaz® (Drospirenone) Marketing and Sales Practices and Products Liability Litigation (MDL 2100), In re: NuvaRing® Products Liability Litigation (MDL 1964), In re: Gadolinium-Based Contrast Products Liability Litigation (MDL 1909), and In re: Ortho Evra® Products Liability Litigation (MDL 1742).

The Pharmaceuticals and Medical Litigation Department at Schlichter, Bogard & Denton aggressively represent clients who allege to have suffered injuries as a result of dangerous pharmaceutical medications and unsafe medical devices. The attorneys at Schlichter, Bogard & Denton, LLP who represent such victims include Roger Denton, Kristine Kraft, Beth Wilkins Flieger, Ashley Brittain Landers, and Tara Rocque. With hard work, creative thinking, and strong trial skills, we have earned an outstanding nationwide reputation by representing thousands of individuals who have suffered serious and life-threatening injuries, or even death.

If you or a loved has suffered injuries as a result of dangerous pharmaceutical medications or unsafe medical devices, please contact the attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.

Schlichter, Bogard & Denton, LLP also welcomes the opportunity to work with other attorneys on these types of cases. Schlichter, Bogard & Denton, LLP is available to either handle these cases or work as co-counsel, so other attorneys are invited to contact an attorney at the firm to explore this opportunity.

The choice of a lawyer is an important decision and should not be based solely on advertisements. The cases discussed do not predict outcomes in future cases. Past results afford no guarantee of future results and every case is different and must be judged on its own merits.


Contact